Applied Therapeutics, Inc. (APLT)

$ 13.74
-1.95 (-12.43%)
-
Symbol APLT
Price $ 13.74
Beta 1.054
Volume Avg. 0.09M
Market Cap 0.36B
Shares () -
52 Week Range 13.04-29.8
1y Target Est -
DCF Unlevered APLT DCF ->
DCF Levered APLT LDCF ->
ROE -95.75% Strong Sell
ROA -75.60% Strong Sell
Operating Margin -
Debt / Equity 21.81% Neutral
P/E -
P/B 3.19 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest APLT news


Dr. Shoshana Shendelman Ph.D.
Healthcare
Biotechnology
Nasdaq Global Market

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company is headquartered in New York City, New York and currently employs 9 full-time employees. The firm is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). The company is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.